NNVC

The company's lead drug candidate is NV-387, which is designed to combat a range of viral infections. This compound is being developed in multiple formulations to treat different conditions. One application targets respiratory viruses like RSV and influenza, for which it has completed initial human clinical trials. The company is also formulating NV-387 into oral products like a syrup and gummies for the potential treatment of COVID-19, which are in early-stage clinical studies to determine appropriate dosing. For more severe respiratory cases, an injectable or inhalable solution of NV-387 is in development, intended to act directly in the lungs against viruses that can cause pneumonia.

Beyond its respiratory programs, NanoViricides is developing other antiviral candidates. These include NV-HHV-1, a topical skin cream for shingles and an oral drug for herpes simplex infections, both of which have undergone non-clinical studies. The company's broader research pipeline, known as its HIVCide program, explores treatments for viruses such as HIV, dengue, and Ebola. Incorporated in 2005, NanoViricides operates as a clinical-stage company, meaning its drug candidates are still undergoing testing and are not yet approved for commercial sale.